Skip to content
Triangle logo TriangleGet started
← Study library

NCT03303950 · REGISTRY CONDITION SEARCH

Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2022-05-05

This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Non-relapse Mortality (NRM) at Day 100

→

outcome · POSTED

Non-relapse Mortality (NRM) at Day 365

→

outcome · POSTED

Incidence of Acute Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Incidence of Chronic GVHD

→

outcome · POSTED

Overall Survival at One Year

→

outcome · POSTED

Disease Free Survival at One Year

→

outcome · POSTED

Number of Participants With Different Clinical Responses

→

outcome · POSTED

Number of Participants With Minimal Residual Disease (MRD) Response

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 * Participants must have one of the following diagnoses of multiple myeloma (MM) or primary/secondary myelofibrosis (MF) * Participants must have histologically documented multiple myeloma (MM) * Participants in early relapse (less than 24 months from initiation of systemic anti-myeloma therapy which may include single or planned tandem autologous transplant) after primary therapy that included and autologous HSCT; OR * Later stage; OR * High risk factors defined by the presence of any one of the following detected at any time prior to enrollment: deletion of chromosome 13 by conventional cytogenetics, hypodiploidy, abnormality in chromosome 1 (1q amplification or 1p deletion), t(4;14), t(14;16), t(14;20) or deletion of 17p by fluorescence in situ hybridization (FISH) or conventional karyotyping; high risk criteria based on commercially available gene expression profiling; OR * Extramedullary disease, plasma cell leukemia or high lactate dehydrogenase (LDH) * Participants must have histologically documented myelofibrosis (MF) * Participants with Dynamic International Prognostic Scoring System (DIPSS) plus intermediate stage 2 or higher risk MF; OR * Subset of intermediate stage 1 participants; defined by: * Poor-risk molecular profile (triple negative: JAK2, CALR, MPL); OR * Presence of any of the following mutations: ASXL1, SRSF2, EZH2, IDH1/2; OR * Severe thrombocytopenia, severe anemia, high peripheral blood blasts percentage; OR * Unfavorable cytogenetic abnormalities (rearrangements of chromosome 5 or 7 or \>= 3 abnormalities * Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines * DONOR: A related donor - fully matched * DONOR: A related donor - haploidentical * DONOR: An unrelated donor - fully matched * DONOR: An unrelated donor -9/10 matched Exclusion Criteria: * Cardiac-left ventricular ejection fraction \< 40%, symptomatic coronary artery disease, or uncontrolled arrhythmias * Pulmonary-forced expiratory volume at one second (FEV1) or diffusion capacity of lung for carbon dioxide (DLCO) \< 40% or history of chronic use of supplemental oxygen. Temporary use of supplemental oxygen at the time of screening or registration is allowed if the investigator feels that the underlying cause of requiring oxygen is reversible by the time treatment begins. * Renal-calculated or measured glomerular filtration rate (GFR) \< 30 ml/min, dialysis-dependent, or history of renal transplant * Hepatic-bilirubin \> 2 X upper limit of normal (ULN) * Alanine aminotransferase (ALT) \> 2.5 X ULN or cirrhosis * Participants with active or uncontrolled bacterial, viral, or fungal infections requiring systemic therapy * Pregnant women, nursing mothers or women of child-bearing potential who are unwilling to use medically accepted methods of contraception * Male and female subjects not willing to agree to medically accepted methods of contraception
healthy Volunteers
false
maximum Age
75 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Participants receive busulfan IV over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo HSCT on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4.
    intervention Names
    1. Drug: Busulfan
    2. Drug: Cyclophosphamide
    3. Drug: Fludarabine
    4. Procedure: Hematopoietic Cell Transplantation
    5. Other: Laboratory Biomarker Analysis
    label
    Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    description
    Given IV
    name
    Busulfan
    other Names
    1. 1, 4-Bis[methanesulfonoxy]butane
    2. BUS
    3. Bussulfam
    4. Busulfanum
    5. Busulfex
    6. Busulphan
    7. CB 2041
    8. CB-2041
    9. Glyzophrol
    10. GT 41
    11. GT-41
    12. Joacamine
    type
    DRUG
  2. arm Group Labels
    1. Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  3. arm Group Labels
    1. Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    description
    Given IV
    name
    Fludarabine
    other Names
    1. Fluradosa
    type
    DRUG
  4. arm Group Labels
    1. Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    description
    Undergo HSCT
    name
    Hematopoietic Cell Transplantation
    other Names
    1. HCT
    2. Hematopoietic Stem Cell Transplantation
    3. HSCT
    4. stem cell transplantation
    type
    PROCEDURE
  5. arm Group Labels
    1. Treatment (busulfan, fludarabine, HSCT, cyclophosphamide)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
6
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    NRM is defined as death due to GVHD, infections, sepsis, organ (lung, liver, kidney) toxicity. Death from underlying disease (i.e. progression or relapse) is not considered NRM.
    measure
    Non-relapse Mortality (NRM) at Day 100
    time Frame
    Up to day 100
secondary Outcomes
  1. description
    NRM is defined as death due to GVHD, infections, sepsis, organ (lung, liver, kidney) toxicity. Death from underlying disease (i.e. progression or relapse) is not considered NRM.
    measure
    Non-relapse Mortality (NRM) at Day 365
    time Frame
    Up to day 365
  2. description
    Cases of acute graft versus host disease (GVHD) will be diagnosed by the treating physician and will be reported as a count of participants with acute GVHD.
    measure
    Incidence of Acute Graft Versus Host Disease (GVHD)
    time Frame
    Up to day 365
  3. description
    Chronic GVHD will be assessed based on criteria established by the National Institutes of Health Consensus Development Project in 2005, and recently updated in 2014. This will be reported as a count of participants diagnosed with chronic GVHD
    measure
    Incidence of Chronic GVHD
    time Frame
    Up to day 365
  4. description
    Overall survival is defined as the number of participants remaining alive up to one year following stem cell transplant.
    measure
    Overall Survival at One Year
    time Frame
    Up to 1 year
  5. description
    Disease free survival is defined as an absence of disease relapse or progression up to one year following stem cell transplant.
    measure
    Disease Free Survival at One Year
    time Frame
    Up to 1 year
  6. description
    Clinical Responses were determined by disease-specific criteria taking into account multiple clinical and molecular markers. Multiple Myeloma (MM) response was determined using International Myeloma Working Group (IMWG) consensus criteria for response. Participants with MM had either Stringent Complete Response (sCR) or Very Good Partial Response (VGPR). Myelofibrosis (MF) response was determined using International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus criteria. Participants with MF had either Complete Response (CR) or Stable Disease (SD) (also referred to in the protocol as no response).
    measure
    Number of Participants With Different Clinical Responses
    time Frame
    Up to 1 year
  7. description
    After bone marrow transplant, bone marrow was collected every 3-6 months (as clinically indicated per treating investigator) for up to one year after bone marrow transplant. Bone marrow was evaluated by a clinical pathologist for any evidence of multiple myeloma (MM) or myelofibrosis (MF). Evidence of MM or MF in the bone marrow is referred to as minimal residual disease (MRD). A participant with evidence of MRD is MRD-positive. A participant with no evidence of MRD is MRD-negative, which is considered an MRD response. This outcome reports the number participants with MRD responses any time between bone marrow transplant up to one year of follow-up.
    measure
    Number of Participants With Minimal Residual Disease (MRD) Response
    time Frame
    Up to 1 year
Full study description
brief Summary
This phase II trial studies how well busulfan, fludarabine, donor stem cell transplant, and cyclophosphamide in treating participants with multiple myeloma or myelofibrosis. Drugs used in chemotherapy, such as busulfan, fludarabine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. When the healthy stem cells from a donor are infused into the participant they may help the participant's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Giving busulfan and fludarabine before and cyclophosphamide after donor stem cell may work better in treating participants with multiple myeloma or myelofibrosis.
detailed Description
PRIMARY OBJECTIVES: I. To evaluate non-relapse mortality (NRM) up to day +100. SECONDARY OBJECTIVES: I. To evaluate non-relapse mortality (NRM) up to day +365. II. To evaluate the incidence of acute graft versus host disease (GVHD) and chronic GVHD up to day +365 post-transplant. III. To evaluate the overall survival and disease free survival up to 1 year. IV. To evaluate clinical response and molecular response (complete response and partial response) up to 1 year. OUTLINE: Participants receive busulfan intravenously (IV) over 2 hours and fludarabine IV over 30 minutes on days -5 to -2. Participants undergo hematopoietic cell transplantation (HSCT) on day 0. Participants then receive cyclophosphamide IV over 60 minutes on days 3 and 4. After completion of study treatment, participants are followed up for 1 year.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-1dc1eb9d3eb62110e9b5
      requested nct id
      NCT03303950
      primary nct id
      NCT03303950
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      4f90a62cac864d887bea1f856fd97d588fc536919951c8bfde3006bbeacfeac0
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-1dc1eb9d3eb62110e9b5
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03303950
      occurrences
      1. context exact
        NCT03303950
        end
        11
        exact text
        NCT03303950
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/905/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      7f30da10023ac2d84df9e9cfe068b98eed09bfbafa7f4484d960dc9fbed1f6d8

    Preserved source evidence · Not medical advice